Gadolinium Deposition Disease Lawsuit
Gadolinium is used as an ingredient in contrast agents which are injected into patients undergoing magnetic resonance imaging (MRI) procedures to enhance the image created by the MRI. There is evidence that gadolinium does not leave the body as quickly as the drug manufacturers promised. Instead, it is being retained in various parts of the body, putting the patient at risk for gadolinium toxicity.
Gadolinium is a chemical element used in MRI and MRA imaging. However, researchers are linking the element to dangerous side effects.
About Gadolinium Deposition Disease
Gadolinium Deposition Disease develops persistent symptoms that arise within two months after the administration of GBCAs.
Gadolinium Deposition Disease Treatment
Treatment for GDD can be costly and expansive. It involves combination of rechelation and immune system modulation.
Recalls and Studies
Researchers have been citing dangers with this chemical agent as early as 1984. Even though the FDA didn’t make any warnings until 2007.
This chemical agent is no stranger to lawsuits as many fell victim to it in the past due to the deadly side affect of Nephrogenic systemic Fibrosis (NSF).
Free Cases Evaulation
Contact us today for a free no-obligation case review. We have over 20 years experience helping injured consumers. There is no obligation.